Pioglitazone and metformin fixed-dose combination in type 2 diabetes mellitus: An evidence-based review of its place in therapy

Giuseppe Derosa, S. A T Salvadeo

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction: Type 2 diabetes mellitus, a metabolic disease with increasing incidence, is one of the most important cardiovascular risk factors. Insulin resistance represents the common mechanism that leads to type 2 diabetes in obese subjects. Metformin and the thiazolidinediones, pioglitazone and rosiglitazone, are insulin-sensitizing agents available for treatment of type 2 diabetes. Large clinical trials have demonstrated the effectiveness of both metformin and pioglitazone in reducing cardiovascular morbidity and mortality. The fixed-dose combination of metformin and pioglitazone appears to be a good option for treating diabetes in insulin-resistant patients. Aims: The purpose of this article is to review the place in therapy of a fixed-dose combination of pioglitazone and metformin in the management of patients with type 2 diabetes. Evidence review: The current evidence suggests that combined therapy may help to achieve the recommended goals in the management of diabetes. A fixed-dose formulation of pioglitazone and metformin may provide advantages in terms of glycemic control and other cardiovascular risk factors frequently associated with diabetes. Place in therapy: The current evidence shows that a fixed-dose formulation of pioglitazone and metformin offers an effective option for the management of patients with type 2 diabetes when monotherapy fails in the achievement of the recommended standards of care.

Original languageEnglish
Pages (from-to)189-198
Number of pages10
JournalCore Evidence
Volume2
Issue number3
Publication statusPublished - 2008

Keywords

  • Cardiovascular risk factors
  • Diabetes
  • Metformin
  • Outcomes
  • Pioglitazone

ASJC Scopus subject areas

  • Medicine(all)
  • Reviews and References, Medical
  • Pharmacology

Fingerprint Dive into the research topics of 'Pioglitazone and metformin fixed-dose combination in type 2 diabetes mellitus: An evidence-based review of its place in therapy'. Together they form a unique fingerprint.

Cite this